Weight-Loss Drugs for Young Children
Quick Facts
Do weight-loss drugs work in elementary-age children?
GLP-1 receptor agonists such as semaglutide and liraglutide mimic a gut hormone that regulates appetite and blood sugar. In adults and adolescents they produce substantial weight reductions. The newly reported study extends this evidence to younger, elementary-age children, a group in which obesity can set the stage for lifelong metabolic risk. Readers should consult the full published results for the magnitude of benefit, side effects and the duration of follow-up.
Regulators have so far approved these medications for children starting at around age 12, after adolescent trials showed meaningful weight loss. Younger children are still growing rapidly and going through key developmental stages, so any treatment in this age group requires careful evaluation of effects on growth, puberty, nutrition and eating behavior, as well as the common gastrointestinal side effects such as nausea, vomiting and diarrhea.
Why is childhood obesity such a pressing health issue?
The US Centers for Disease Control and Prevention reports that roughly 20 percent of children and adolescents in the United States have obesity. Excess weight in childhood is associated with early cardiometabolic problems, including prediabetes, hypertension, dyslipidemia and metabolic dysfunction-associated steatotic liver disease, along with sleep apnea, joint strain and increased risk of depression and weight stigma. Children with obesity are more likely to have obesity as adults.
The 2023 American Academy of Pediatrics clinical practice guideline emphasized that obesity is a chronic disease with biological drivers, not a failure of willpower, and recommended intensive health behavior and lifestyle treatment for all affected children, with medication to be considered for adolescents 12 and older and surgery for some older teens. Evidence from younger children could prompt reconsideration of how early medication is appropriate.
What questions remain before wider use in young children?
Obesity medications generally work only while they are taken, and weight regain after discontinuation is common in adolescents and adults. For a child, this could imply treatment lasting many years, making long-term safety data critical. Researchers also need to monitor nutrient intake, bone health, linear growth and psychological well-being, as well as ensure that medication does not encourage disordered eating.
Access and equity are additional concerns. These drugs are expensive, insurance coverage varies, and supply has been limited at times. Pediatric experts generally stress that medication should complement, not replace, family-based lifestyle support, including balanced nutrition, physical activity, adequate sleep and reduced sugary drink intake. Families considering any treatment should discuss options with a pediatrician or pediatric obesity specialist.
Frequently Asked Questions
Approvals for GLP-1 based medications in children have generally started at age 12 and older. Use in younger children is currently investigational, and approval would depend on regulatory review of trial data.
The most common side effects are gastrointestinal, including nausea, vomiting, diarrhea and constipation. Clinicians also monitor growth, nutrition and mood.
Yes. Guidelines from the American Academy of Pediatrics recommend intensive health behavior and lifestyle treatment as the foundation of care, with medication as an added option in selected cases.
References
- Wall Street Journal. Weight-Loss Drugs for Elementary-Age Children Succeed in Study. November 2026.
- Hampl SE, et al. Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents With Obesity. Pediatrics. 2023 (American Academy of Pediatrics).
- Centers for Disease Control and Prevention. Childhood Obesity Facts.